Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06518382

Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients

A Retrospective Observational Study Characterizing Tumour-microenvironment Spatial Interaction Aimed at the Identification of New Markers of Resistance to Therapy in HER2-positive Breast Cancer Patients

Status
Recruiting
Phase
Study type
Observational
Enrollment
10 (estimated)
Sponsor
Giampaolo Bianchini · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This retrospective observational study aims at the comparison of the tumour-microenvironment tissue architecture before and after neo-adjuvant therapy in samples from HER2-positive (HER2+) breast cancer (BrCa) patients that display residual invasive disease in the breast/lymph node at surgery after standard-of-care combined chemotherapy and trastuzumab treatment. The working hypothesis of the investigators is that: Therapy imposes a selective pressure on tumour-microenvironment features promoting resistance to treatment. Participant that have already undergone neo-adjuvant treatment as part of their regular medical care for HER2-positive breast cancer will provide access to formalin-fixed paraffin-embedded (FFPE) samples taken before and after therapy. Tumoral, peri-tumoral and stromal regions of each specimen will be analyzed with the ultimate goal to identify new biomarkers (and putative targets) of resistance to therapy.

Conditions

Timeline

Start date
2024-12-10
Primary completion
2026-12-01
Completion
2027-08-01
First posted
2024-07-24
Last updated
2026-04-15

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06518382. Inclusion in this directory is not an endorsement.